Abstracts tagged "Juvenile idiopathic arthritis (JIA) and pregnancy"

Abstract Number: 2435 • 2015 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Adult Juvenile Idiopathic Arthritis Patients Treated with Biologic Agents
Katerina Jarosova¹, Katerina Andelova², Karel Hejduk³, Michal Uher³ and Jiri Vencovsky⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²clinical, Institute for the Care for Mother and Child, Prague, Czech Republic, ³Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Charles University, Prague, Czech Republic
Background/Purpose: Biologic drugs are effective therapeutic option in patients with juvenile idiopathic arthritis (JIA). However, data regarding the use during pregnancy and breastfeeding in adult…
Abstract Number: 1169 • 2012 ACR/ARHP Annual Meeting
Obstetrical Complications in Women with Juvenile Idiopathic Arthritis
Evelyne Vinet¹, Sasha Bernatsky², Mohammed Kaouache², Christian A. Pineau³, Ann E. Clarke⁴, Elizabeth Hazel⁵, Ciaran M. Duffy⁶, Anick Bérard⁷ and Debbie Ehrmann Feldman⁸, ¹McGill University Health Center, Montreal, QC, Canada, ²Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, Canada, ⁵Rhematology, McGill University Health Centre, Montreal, QC, Canada, ⁶Rheumatology, Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁷Université de Montréal, Montréal, QC, Canada, ⁸Rehabilitation, Université de Montréal, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) most often affects women before childbearing age. Patients with JIA and their parents often ask about the potential impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].